155 related articles for article (PubMed ID: 10699898)
1. Cutaneous fibrosis induced by docetaxel: a case report.
Cleveland MG; Ajaikumar BS; Reganti R
Cancer; 2000 Mar; 88(5):1078-81. PubMed ID: 10699898
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel.
Leahy M; Howell A
Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
[TBL] [Abstract][Full Text] [Related]
3. Paclitaxel and docetaxel in breast and ovarian cancer.
Drug Ther Bull; 1997 Jun; 35(6):43-6. PubMed ID: 9282422
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel: a review of its pharmacology and clinical activity.
Trudeau ME
Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
[TBL] [Abstract][Full Text] [Related]
5. Treatment side effects. Case 2. Toxic, epidermal, necrolysis-like reaction associated with docetaxel chemotherapy.
Dourakis SP; Sevastianos VA; Alexopoulou A; Deutsch M; Stavrianeas N
J Clin Oncol; 2002 Jul; 20(13):3030-2. PubMed ID: 12089234
[No Abstract] [Full Text] [Related]
6. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
7. Docetaxel (Taxotere) for advanced breast cancer.
Med Lett Drugs Ther; 1996 Sep; 38(984):87-8. PubMed ID: 8828520
[No Abstract] [Full Text] [Related]
8. Doxorubicin followed by docetaxel versus docetaxel followed by doxorubicin in the adjuvant treatment of node positive breast cancer: results of a feasibility study.
Cardoso F; Ferreira Filho AF; Crown J; Dolci S; Paesmans M; Riva A; Di Leo A; Piccart MJ
Anticancer Res; 2001; 21(1B):789-95. PubMed ID: 11299845
[TBL] [Abstract][Full Text] [Related]
9. Docetaxel-induced radiation recall dermatitis and successful rechallenge without recurrence.
Camidge DR; Kunkler IH
Clin Oncol (R Coll Radiol); 2000; 12(4):272-3. PubMed ID: 11005698
[No Abstract] [Full Text] [Related]
10. Scleroderma in association with the use of docetaxel (taxotere) for breast cancer.
Hassett G; Harnett P; Manolios N
Clin Exp Rheumatol; 2001; 19(2):197-200. PubMed ID: 11326485
[TBL] [Abstract][Full Text] [Related]
11. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
Ravdin PM; Valero V
Semin Oncol; 1995 Apr; 22(2 Suppl 4):17-21. PubMed ID: 7740326
[TBL] [Abstract][Full Text] [Related]
12. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
D'Andrea GM; Seidman AD
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
[TBL] [Abstract][Full Text] [Related]
13. Nail changes secondary to docetaxel (Taxotere).
Correia O; Azevedo C; Pinto Ferreira E; Braga Cruz F; Polónia J
Dermatology; 1999; 198(3):288-90. PubMed ID: 10393455
[TBL] [Abstract][Full Text] [Related]
14. Is weekly docetaxel an active and gentle chemotherapy in the treatment of metastatic breast cancer?
Maisano R; Mare M; Zavettieri M; Caristi N; Mesiti M; Scisca C; La Torre F
Anticancer Res; 2003; 23(2C):1923-6. PubMed ID: 12820480
[TBL] [Abstract][Full Text] [Related]
15. Severe syndrome of inappropriate antidiuretic hormone secretion with docetaxel treatment in metastatic breast cancer.
Langer-Nitsche C; Lück HJ; Heilmann M
Acta Oncol; 2000; 39(8):1001. PubMed ID: 11206991
[No Abstract] [Full Text] [Related]
16. [Yellow nails].
Auvinet M; Dahan S; Dingremont C; Ollier S; Juchet H; Arlet P
Rev Med Interne; 1998 May; 19(5):353-4. PubMed ID: 9775172
[No Abstract] [Full Text] [Related]
17. Treatment of patients resistant to paclitaxel therapy.
Valero V
Anticancer Drugs; 1996 Aug; 7 Suppl 2():17-9. PubMed ID: 8862705
[TBL] [Abstract][Full Text] [Related]
18. Docetaxel (Taxotere): a highly active taxoid with manageable toxicity.
Aapro MS
Semin Oncol; 1995 Apr; 22(2 Suppl 4):1-2. PubMed ID: 7740325
[No Abstract] [Full Text] [Related]
19. Docetaxel and autonomic cardiovascular control in anthracycline treated breast cancer patients.
Ekholm E; Rantanen V; Bergman M; Vesalainen R; Antila K; Salminen E
Anticancer Res; 2000; 20(3B):2045-8. PubMed ID: 10928149
[TBL] [Abstract][Full Text] [Related]
20. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer.
van Oosterom AT
Semin Oncol; 1995 Dec; 22(6 Suppl 13):22-8. PubMed ID: 8604449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
